Pharmaceutically acceptable salts of a benzothiophene-substituted fused ring compound, crystalline forms thereof, and uses thereof
By preparing KRAS G12D inhibitors in various pharmaceutically usable salt forms, the shortcomings of existing compounds in terms of physicochemical and pharmaceutical properties have been overcome, providing stable crystal forms and enhancing the efficacy of the compounds in cancer treatment.
CN119613432BActive Publication Date: 2026-06-16SUZHOU SUNCADIA BIOPHARM CO LTD +1
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SUZHOU SUNCADIA BIOPHARM CO LTD
- Filing Date
- 2024-12-20
- Publication Date
- 2026-06-16
Smart Images
Figure CN119613432B_ABST
Abstract
The present disclosure relates to a pharmaceutically acceptable salt of a benzothiophene-substituted fused ring compound, a crystalline form thereof and uses. Specifically, the present disclosure provides a pharmaceutically acceptable salt of 2-amino-7-fluoro-4-((5S,5aS,6S,9R)-1-fluoro-12-((1-((4-(fluoromethylidene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-5-methyl-5a,6,7,8,9,10-hexahydro-5H-4-oxa-3,10a,11,13,14-pentaaza-6,9-methanonaphtho[1,8-ab]heptalen-2-yl)benzo[b]thiophene-3-carbonitrile, a crystalline form thereof and a preparation method thereof, and the corresponding salt has good stability and can be better used for clinical treatment.
Need to check novelty before this filing date? Find Prior Art